{
    "nctId": "NCT00070564",
    "briefTitle": "S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer",
    "officialTitle": "Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 3294,
    "primaryOutcomeMeasure": "Disease-free Survival",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed stage I-III invasive breast cancer\n\n  * Operable disease\n  * Stage I, II, IIIA, and IIIC (T1-3, N3a only)\n  * No T4 tumors\n* High-risk disease, defined by 1 of the following:\n\n  * Tumor \u2265 2 cm in greatest diameter (includes both invasive and intraductal component)\n\n    * Patients with nodal status of N0+ (i.e., no cluster of tumor cells in any node greater than 0.2 mm) are considered to be node negative and must have a primary tumor \u2265 2 cm in size or have a tumor \u2265 1 cm with high risk features\n    * Patients who are node negative on the basis of a sentinel node procedure and fewer than 6 axillary nodes are removed are eligible OR at least 6 axillary or intramammary nodes must be negative\n  * Tumor \u2265 1 cm in diameter and meeting 1 of the following criteria:\n\n    * ER-negative and PgR-negative\n    * ER-positive or PgR-positive with a Genomic Health Recurrence Score of \u2265 26\n  * One or more axillary or intramammary nodes are involved by metastatic breast cancer\n\n    * If one or more nodes is involved, a minimum of 6 axillary or intramammary nodes must have been examined histologically\n    * Patients with N0(I+) disease will be considered node negative\n* HER2/neu-positive tumors (3+ by immunohistochemical staining or amplified by fluorescence in-situ hybridization) allowed\n* Bilateral synchronous breast cancer diagnosed within 1 month of each other allowed provided the higher TNM stage primary tumor meets the eligibility criteria\n* Prior modified radical mastectomy OR local excision of all tumors with axillary lymph node dissection or sentinel node resection required\n\n  * No more than 84 days since prior surgery for the primary tumor and/or axilla\n  * Final resection margins for the primary tumor must be histologically negative for invasive cancer and ductal carcinoma in situ\n  * Resection margins positive for lobular carcinoma in situ are allowed\n* Hormone receptor status:\n\n  * Estrogen receptor status known\n  * Progesterone receptor status known\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Male or female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* Zubrod 0-2\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Absolute neutrophil count at least 1,200/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n\nHepatic\n\n* Bilirubin no greater than upper limit of normal (ULN)\n* Alkaline phosphatase no greater than 2 times ULN\n* SGOT or SGPT no greater than 2 times ULN\n\nRenal\n\n* Creatinine no greater than ULN\n\nCardiovascular\n\n* No congestive heart failure\n* No active angina pectoris\n* LVEF greater than or equal to the lower limit of normal\\* by MUGA or echocardiogram NOTE: Patients age 60 and over OR with a history of hypertension\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, in situ cervical carcinoma, or lobular carcinoma in situ of the breast\n\n  * Prior invasive breast cancer or ductal carcinoma in situ allowed if disease-free for 5 years\n* HIV negative\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* No prior cytotoxic chemotherapy for this breast cancer\n* No prior chemotherapy with an anthracycline, anthracenedione, or taxane\n\nEndocrine therapy\n\n* Not specified\n\nRadiotherapy\n\n* No prior radiotherapy for this malignancy\n* At least 2 weeks since prior radiotherapy for ductal carcinoma in situ\n\nSurgery\n\n* See Disease Characteristics",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}